Charles Schwab’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $475K | Sell |
331,897
-142,946
| -30% | -$204K | ﹤0.01% | 3155 |
|
|
2025
Q1 | $760K | Sell |
474,843
-11,523
| -2% | -$18.4K | ﹤0.01% | 2941 |
|
|
2024
Q4 | $1.75M | Buy |
486,366
+3,437
| +0.7% | +$12.4K | ﹤0.01% | 2717 |
|
|
2024
Q3 | $2.75M | Sell |
482,929
-6,029
| -1% | -$34.4K | ﹤0.01% | 2606 |
|
|
2024
Q2 | $2.26M | Buy |
488,958
+221,529
| +83% | +$1.02M | ﹤0.01% | 2669 |
|
|
2024
Q1 | $2.18M | Buy |
267,429
+14,719
| +6% | +$120K | ﹤0.01% | 2562 |
|
|
2023
Q4 | $1.43M | Buy |
252,710
+4,458
| +2% | +$25.2K | ﹤0.01% | 2712 |
|
|
2023
Q3 | $462K | Buy |
248,252
+17,218
| +7% | +$32K | ﹤0.01% | 3066 |
|
|
2023
Q2 | $635K | Sell |
231,034
-85,975
| -27% | -$236K | ﹤0.01% | 2940 |
|
|
2023
Q1 | $995K | Sell |
317,009
-39,643
| -11% | -$124K | ﹤0.01% | 2733 |
|
|
2022
Q4 | $2.1M | Buy |
356,652
+4,527
| +1% | +$26.7K | ﹤0.01% | 2560 |
|
|
2022
Q3 | $3.09M | Buy |
352,125
+78,936
| +29% | +$692K | ﹤0.01% | 2452 |
|
|
2022
Q2 | $2.06M | Buy |
273,189
+52
| +0% | +$392 | ﹤0.01% | 2561 |
|
|
2022
Q1 | $6.63M | Buy |
273,137
+8,486
| +3% | +$206K | ﹤0.01% | 2150 |
|
|
2021
Q4 | $8.52M | Buy |
264,651
+4,199
| +2% | +$135K | ﹤0.01% | 2081 |
|
|
2021
Q3 | $11.6M | Buy |
260,452
+119,858
| +85% | +$5.36M | ﹤0.01% | 1915 |
|
|
2021
Q2 | $5.32M | Buy |
140,594
+70,882
| +102% | +$2.68M | ﹤0.01% | 2318 |
|
|
2021
Q1 | $2.58M | Buy |
69,712
+2,970
| +4% | +$110K | ﹤0.01% | 2590 |
|
|
2020
Q4 | $2.21M | Buy |
+66,742
| New | +$2.21M | ﹤0.01% | 2566 |
|